Get the latest tech news
The end of compounded GLP-1 drugs leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from
Blockbuster obesity and diabetes drugs — such as Wegovy, Ozempic, and Mounjaro — are no longer deemed by regulators to be in shortage, so compounding pharmacies and the telehealth companies they work with must stop offering copies of the treatments. Now, hundreds of thousands of patients are stuck navigating uncharted waters as companies they entrusted with their health pursue strategies that may disrupt their care or present risks. “This is kind of like a lose-lose situation,” said Reshma Ramachandran, an assistant professor and health services researcher at Yale University who treats many patients who have turned to compounded GLP-1s because they can’t afford the branded drugs.
Or read this on Hacker News